1795 Mei-Shih: Alvogen Korea Subsidiary Secures Korean Approval for Anti-PD-1 Antibody SERPLUMAR
NQ Score
87/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Mei-Shih (1795)'s subsidiary Alvogen Korea has obtained South Korean approval for SERPLUMAR (serplulimab), an anti-PD-1 monoclonal antibody developed with Shanghai Fosun Honglin, for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), advancing Mei-Shih's oncology footprint in Asia.
AI Analysis
Frequently Asked Questions
- Q: What product did Mei-Shih's subsidiary Alvogen Korea get approved?
- A: SERPLUMAR (serplulimab), an anti-PD-1 monoclonal antibody.
- Q: What disease is this product used for?
- A: First-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in South Korea.
- Q: Which agency granted the approval?
- A: South Korea's Ministry of Food and Drug Safety (MFDS).
- Q: Which company developed SERPLUMAR?
- A: Fosun Honglin independently developed this humanized anti-PD-1 monoclonal antibody.
- Q: What is the significance of this approval for Mei-Shih?
- A: It strengthens Mei-Shih's oncology market presence and strategic positioning in Asia.